WO2000059890A1 - Derives de tetrahydropyridazine - Google Patents
Derives de tetrahydropyridazine Download PDFInfo
- Publication number
- WO2000059890A1 WO2000059890A1 PCT/EP2000/002275 EP0002275W WO0059890A1 WO 2000059890 A1 WO2000059890 A1 WO 2000059890A1 EP 0002275 W EP0002275 W EP 0002275W WO 0059890 A1 WO0059890 A1 WO 0059890A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzoyl
- tetrahydro
- pyridazine
- methoxyphenyl
- ethoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention relates to tetrahydropyridazine derivatives selected from the
- Q is absent or alkylene with 1-6 C atoms
- R 1 , R 2 each independently of one another -OH, OR 5 , -SR 5 ,
- R 1 and R 2 together also -O-CH 2 -O-,
- R 5 and R are each independently A, cycloalkyl with 3-7
- the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments. It has been found that the compounds according to the invention and their salts have very valuable pharmacological properties with good tolerability.
- PDE IV inhibition can e.g. analogous to C.W. Davis in Biochim. biophys. Acta 797, 354-362 (1984).
- the compounds according to the invention can be used for the treatment of asthmatic diseases.
- the anti-asthmatic effect of the PDE IV inhibitors is e.g. by TJ. Torphy et al. in Thorax, 46, 512-523 (1991) and can e.g. B. by the method of T. Olson, Acta allergologica 26, 438-447 (1971) can be determined.
- the compounds according to the invention can used to treat osteoporosis.
- the compounds also show an inhibitory effect on the formation of TNF (tumor necrosis factor) and are therefore suitable for the treatment of allergic and inflammatory diseases, autoimmune diseases and graft rejection reactions. They can be used to treat memory disorders, tumors, atherosclerosis, rheumatoid arthritis, multiple sclerosis, Crohn's disease, atopic dermatitis, diabetes mellitus, ulcerative colitis and AIDS.
- TNF tumor necrosis factor
- PDE IV inhibitors in the treatment of asthma, inflammatory diseases, diabetes mellitus, atopic dermatitis, psoriasis, AIDS, tumor growth or tumor metastases is described, for example, in EP 77 92 91.
- the anti-inflammatory effect of the substances according to the invention and their effectiveness for the treatment of, for example, autoimmune diseases, multiplesclerosis or rheumatoid arthritis can be analogous to the methods of N. Sommer et al., Nature Medicine, 1, 244-248 (1995) or L. Sekut et al., Clin. Exp. Immunol., 100, 126-132 (1995).
- the compounds according to the invention can be used as active pharmaceutical ingredients in human and veterinary medicine. They can also be used as intermediates for the production of further active pharmaceutical ingredients.
- R 1 and R 2 have the meanings given for formula I and
- R and R each independently of one another denote H or alkyl
- R 1 , R 2 , R 3 , R 4 and Q have the meanings given, with a compound of the formula V.
- L is Cl, Br, OH or a reactive esterified OH group
- the compounds of formula I can have a chiral center and can therefore occur in several stereoisomeric forms. All of these forms (e.g. R and S forms) and their mixtures (e.g. the R, S forms) are included in Formula I.
- Solvates are hydrates or e.g. Alcoholates, such as the addition compounds with methanol, ethanol or isopropanol.
- a and A ' is preferably alkyl, more preferably alkyl substituted by 1 to 5 fluorine and / or chlorine atoms.
- alkyl is preferably unbranched and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, preferably 1, 2, 3, 4 or 5 carbon atoms and is preferably methyl , Ethyl, trifluoromethyl, pentafluoroethyl or propyl, further preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl or isopentyl.
- Cycloalkyl preferably has 3-7 C atoms and is preferably cyclopropyl and cyclobutyl, further preferably cyclopentyl or cyclohexyl, and also cycloheptyl.
- Methyl cycloalkyl preferably has 4-8 C atoms and preferably represents methylene cyclopropyl and methylene cyclobutyl, further preferably methylene cyclopentyl and methylene cyclohexyl, and also methylene cycloheptyl.
- Alkenyl preferably stands for vinyl, 1- or 2-propenyl, 1-butenyl, isobutenyl, sec-butenyl, further preferred is 1-pentenyl, isopentyl or 1-hexenyl.
- Alkylene is preferably unbranched and is preferably methylene or ethylene, more preferably propylene or butylene.
- R 3 and R 4 one is preferably H, while the other is preferably propyl or butyl, but particularly preferably ethyl or methyl.
- the radicals R 1 and R 2 can be the same or different and are in the 3- or 4-position of the phenyl ring. They mean, for example, independently of one another hydroxy, -S-CH 3 , -SO-CH 3 , -SO 2 CH 3 , F, Cl, Br or I or together methylenedioxy. However, they are particularly preferably each methoxy, ethoxy, propoxy, cyclopentoxy, or else fluorine, difluoro, trifluoromethoxy, 1-fluorine, 2-fluorine, 1, 2-difluoro, 2,2-difluoro, 1, 2,2-trifluoro or 2,2,2-trifluoroethoxy.
- the radical B is preferably 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferably 1,2,3-triazoM-, -4- or -5-yI, 1, 2,4-triazoM-, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4- or -5-yl, 1, 2,4-oxadiazol-3- or - 5-yl, 1, 3,4- Thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol-3- or -5-yl, 1, 2,3-thiadiazol-4- or -5-y
- the radical B is preferably also methyl, ethyl, propyl, n-butyl, methoxy, ethoxy, propoxy, N-methylamino, N, N-dimethylamino, N-ethylamino or N, N-diethylamino. It applies to the entire invention that all radicals which occur more than once can be the same or different, ie are independent of one another.
- the compounds of the invention and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (for example in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart) are, under reaction conditions that are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail.
- R 1 , R 2 , R 3 , R 4 and Q have the meanings indicated, in particular the preferred meanings indicated.
- Q is preferably methylene or ethylene, more preferably propylene or butylene.
- B has the preferred meanings indicated in the compounds of the formulas III and V, while L denotes Cl, Br, OH or a reactive esterified OH group.
- L is a reactive esterified OH group, this is preferably alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyioxy with 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy, further also 2- Naphthalenesulfonyloxy).
- the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds according to the invention. On the other hand, it is possible to carry out the reaction in stages.
- the compounds according to the invention can preferably be obtained by reacting compounds of the formula II with compounds of the formula III.
- the compounds of the formula II are reacted with the compounds of the formula III in the presence or absence of an inert solvent at temperatures between about -20 and about 150 °, preferably between 20 and 100 °.
- Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF);
- the compounds according to the invention can furthermore be obtained by reacting compounds of the formula IV with compounds of the formula V.
- the starting compounds of the formulas IV and V are generally known. If they are not known, they can be produced by methods known per se. For example, the production of 1-benzoyl-tetrahydropyridazine is described in J. Med. Chem. 38, 4878 (1995).
- the radical -CO-L denotes a preactivated carboxylic acid, preferably a carboxylic acid halide.
- reaction of the compounds of the formula IV with compounds of the formula V takes place under the same conditions, with regard to the reaction time, temperature and solvent, as is described for the reaction of the compounds of the formula II with compounds of the formula III.
- a base of the compounds according to the invention can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanoi and subsequent evaporation.
- acids that provide physiologically acceptable salts are suitable for this implementation.
- So inorganic acids can be used, e.g. Sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, also organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heteroeyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
- Formic acid acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane or ethanesulfonic acid -Hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalene mono- and disulfonic acids, lauryl sulfuric acid. Salts with physiologically unacceptable acids, e.g. Picrates can be used for the isolation and / or purification of the compounds of the formula I.
- Picrates can be used for the isolation and / or purification of the compounds of the formula I.
- the invention further relates to the use of the compounds according to the invention and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route.
- they can be combined with at least one solid, liquid and / or semi-liquid carrier or auxiliary and if necessary, in combination with one or more other active ingredients are brought into a suitable dosage form.
- the invention also relates to medicaments of the compounds according to the invention selected from the group
- the invention further relates to pharmaceutical preparations containing at least one compound according to the invention and / or one of its physiologically acceptable salts or solvates.
- Suitable carrier substances are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and with the new compounds not react, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
- Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used for oral use, suppositories for rectal use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for topical use for parenteral use Ointments, creams or powder.
- the new compounds can also be lyophilized and the lyophilisates obtained used, for example, for the production of injection preparations.
- the specified preparations can be sterilized and / or auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colors, flavors and / or one or more other active substances contain, for example, one or more vitamins.
- auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colors, flavors and / or one or more other active substances contain, for example, one or more vitamins.
- the compounds according to the invention and their physiologically acceptable salts can be used in the control of diseases in which an increase in the cAMP (cyclo-adenosine monophosphate) level leads to inhibition or prevention of inflammation and muscle relaxation.
- the compounds according to the invention can be used particularly in the treatment of allergies, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases and autoimmune diseases.
- the substances according to the invention are generally preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
- the daily dosage is preferably between about 0.02 and 10 mg / kg body weight.
- the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination and combination of drugs and severity of the disease to which the therapy applies. Oral application is preferred.
- the compounds according to the invention can contain one or more centers of asymmetry. In this case, they are usually in racemic form. Racemates obtained can be separated into their enantiomers mechanically or chemically by methods known per se. Diastereomers are preferably formed from the racemic mixture by reaction with an optically active release agent.
- optically active compounds by the methods described above by using starting materials that are already optically active.
- customary work-up means: if necessary, water is added, if necessary, depending on the constitution of the end product, the pH is adjusted to between 2 and 10, extracted with ethyl acetate or dichloromethane, and the mixture is separated off, dries the organic phase over sodium sulfate, evaporates and purifies by chromatography on silica gel and / or by crystallization.
- a suspension of 4.70 g of 3- (3,4-dimethoxyphenyl) -1, 4,5,6-tetrahydropyridazine ("A") in 150 ml of THF is mixed with 2.24 g of potassium tert-butoxide and stirred for 30 minutes.
- 7.3 g of 4-nicotinoylaminobenzoyl chloride are added and the mixture is subsequently stirred at room temperature for 10 hours. The solvent is removed and worked up as usual.
- the compound is obtained analogously by reaction with potassium cyanate 1 - (4-ureido-benzoyl) -3- (3-ethoxy-4-methoxy-phenyl) -1, 4,5,6-tetrahydro-pyridazine, mp 251 °.
- Example A Injection glasses
- a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.
- a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
- a solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2 PO 4 .2H 2 O, 28.48 g of Na 2 HPO 4 .12H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
- Example D ointment
- 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
- Example E tablets A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
- Example F coated tablets
- Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
- Example G capsules
- each capsule contains 20 mg of the active ingredient.
- a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32897/00A AU3289700A (en) | 1999-04-06 | 2000-03-15 | Tetrahydropyridazine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19915365.5 | 1999-04-06 | ||
DE19915365A DE19915365A1 (de) | 1999-04-06 | 1999-04-06 | Tetrahydropyridazin-Derivate |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000059890A1 true WO2000059890A1 (fr) | 2000-10-12 |
Family
ID=7903584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/002275 WO2000059890A1 (fr) | 1999-04-06 | 2000-03-15 | Derives de tetrahydropyridazine |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR023262A1 (fr) |
AU (1) | AU3289700A (fr) |
DE (1) | DE19915365A1 (fr) |
WO (1) | WO2000059890A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000059484A2 (fr) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Utilisation d'arylalcanoylpyridazines |
WO2003037349A1 (fr) * | 2001-10-31 | 2003-05-08 | Merck Patent Gmbh | Inhibiteurs de la phosphodiesterase de type 4 et leurs utilisations |
WO2010099217A1 (fr) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine |
EP2258357A2 (fr) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenèse avec inhibiteur de l'acetylcholinestérase |
EP2275095A2 (fr) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese par modulation des recepteurs muscariniques |
EP2314289A1 (fr) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Modulation de la neurogenese dont la médiation est assurée par récepteur gaba |
WO2011063115A1 (fr) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
WO2011091033A1 (fr) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation de la neurogenèse par des agents ppar |
EP2377531A2 (fr) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogénèse par modulation de l'angiotensine |
WO2013106547A1 (fr) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1235589C (zh) * | 2001-02-12 | 2006-01-11 | 默克专利股份公司 | 4型磷酸二酯酶抑制剂在制备治疗心肌疾病药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19632549A1 (de) * | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
-
1999
- 1999-04-06 DE DE19915365A patent/DE19915365A1/de not_active Withdrawn
-
2000
- 2000-03-15 AU AU32897/00A patent/AU3289700A/en not_active Withdrawn
- 2000-03-15 WO PCT/EP2000/002275 patent/WO2000059890A1/fr active Search and Examination
- 2000-04-05 AR ARP000101548A patent/AR023262A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19632549A1 (de) * | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
WO1998006704A1 (fr) * | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalcanoylpyridazines |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000059484A2 (fr) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Utilisation d'arylalcanoylpyridazines |
WO2000059484A3 (fr) * | 1999-04-06 | 2001-08-23 | Merck Patent Gmbh | Utilisation d'arylalcanoylpyridazines |
WO2003037349A1 (fr) * | 2001-10-31 | 2003-05-08 | Merck Patent Gmbh | Inhibiteurs de la phosphodiesterase de type 4 et leurs utilisations |
EP2275096A2 (fr) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese par modulation des recepteurs muscariniques |
EP2258358A2 (fr) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenèse avec un inhibiteur de l'acetylcholinestérase |
EP2258359A2 (fr) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline |
EP2275095A2 (fr) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese par modulation des recepteurs muscariniques |
EP2258357A2 (fr) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenèse avec inhibiteur de l'acetylcholinestérase |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
EP2377530A2 (fr) | 2005-10-21 | 2011-10-19 | Braincells, Inc. | Modulation de neurogénèse par inhibition PDE |
EP2314289A1 (fr) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Modulation de la neurogenese dont la médiation est assurée par récepteur gaba |
EP2377531A2 (fr) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogénèse par modulation de l'angiotensine |
EP2382975A2 (fr) | 2006-05-09 | 2011-11-02 | Braincells, Inc. | Neurogénèse par modulation d'angiotensine |
WO2010099217A1 (fr) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine |
WO2011063115A1 (fr) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse |
WO2011091033A1 (fr) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation de la neurogenèse par des agents ppar |
WO2013106547A1 (fr) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation |
Also Published As
Publication number | Publication date |
---|---|
DE19915365A1 (de) | 2000-10-12 |
AU3289700A (en) | 2000-10-23 |
AR023262A1 (es) | 2002-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0922036B1 (fr) | Arylalcanoylpyridazines | |
EP0763534B1 (fr) | Dérivés d'arylalkyl-diazinone en tant qu'inhibiteurs de la phosphodiestérase de type IV | |
EP1226143B1 (fr) | Derives d'imidazopyridine comme inhibiteurs de phosphodiesterase vii | |
EP1087946B1 (fr) | Arylalcanoylpyridazines | |
EP0934301A1 (fr) | Amides d'acide carboxylique d'aminothiophene et leur utilisation comme inhibiteurs de phosphodiesterase | |
EP1124809B1 (fr) | Benzoylpyridazines | |
EP0738715B1 (fr) | Arylalkyl-pyridazinones | |
EP1228073B1 (fr) | Composes imidazole utilises comme inhibiteurs de la phosphodiesterase vii | |
WO2000059890A1 (fr) | Derives de tetrahydropyridazine | |
DE19604388A1 (de) | Arylalkyl-diazinone | |
EP0723962B1 (fr) | Arylalkyl-thiadiazinones | |
EP1225896A1 (fr) | Derives d'isoxazol utilises comme inhibiteurs vii de phosphodiesterase | |
DE10064997A1 (de) | Benzoylpyridazine | |
EP1143944A3 (fr) | Utilisation d'arylalcanoylpyridazines | |
EP1194411B1 (fr) | Benzolpyridazines | |
EP1406878A1 (fr) | Derives de 4-(benzylidene-amino)-3-(methylsulfanyle)-4h-(1, 2, 4) triazin-5-one a effet inhibiteur de pde-iv et antagoniste de tnf pour le traitement des maladies cardiaques et des allergies | |
WO2003008373A1 (fr) | Hydrazides de tyrosine | |
DE19653024A1 (de) | Endothelin-Rezeptor-Antagonisten | |
DE10156230A1 (de) | Tyrosinhydrazide | |
DE10156229A1 (de) | Triazinderivate | |
DE10135009A1 (de) | Triazinderivate | |
DE10135248A1 (de) | Tyrosinhydrazide | |
EP0647627A1 (fr) | Dihydro-1,2 oxo-2 méthylsulfonylaminométhyl-3 pyridines comme antagonistes d'angiotensine II |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |